Bill is a Member in the firm's Corporate & Securities Section. Currently, he serves as Co-Chair of the Life Sciences Practice Group. Bill's practice is focused primarily in the areas of securities law, venture capital and mergers and acquisitions. He regularly represents technology-based companies, principally in the areas of biotechnology, medical technologies, energy and clean technology, and software. Bill routinely counsels these clients on many aspects of their corporate development, from initial organization and acquisition of technology, through private financing and initial public offering, to strategic alliances and business combination transactions. He also regularly represents venture capital firms in portfolio investment activities and underwriters in public offerings and private placements of equity securities. Recent representative transactions include: Mergers and Acquisitions · Represented Caliper Life Sciences, Inc. (Nasdaq : CALP) in its merger with PerkinElmer Inc. (NYSE : PKI) · Represented Visigen Biotechnologies, Inc. in its merger with Invitrogen Corporation (currently known as Life Technologies, Inc. (Nasdaq : LIFE)) · Represented V.I. Technologies, Inc. (Nasdaq : VITX) in its merger with Panacos Pharmaceuticals, Inc. (Nasdaq : PANC) · Represented EPIX Pharmaceuticals, Inc. (Nasdaq : EPIX) in its merger with Predix Pharmaceuticals, Inc. · Represented Caliper Life Sciences, Inc. (Nasdaq : CALP) in its merger with Xenogen Corporation (Nasdaq : XGEN) · Represented Focus Technologies Holding Company in its acquisition by Quest Diagnostics Incorporated (NYSE : DGX) · Represented Alteon Inc. (AMEX : ALT) in its merger with HaptoGuard, Inc. · Represented The MacGregror Group, Inc. in its acquisition by Investment Technology Group, Inc. (NYSE : ITG) Public and Private Offerings for Public Companies · Represented BG Medicine, Inc. (Nasdaq : BGMD) in its initial public offering · Represented Coley Pharmaceutical Group, Inc. (Nasdaq : COLY) in its initial public offering · Represented Panacos Pharmaceuticals, Inc. (Nasdaq : PANC) in a follow-on public offering · Represented EPIX Pharmaceuticals, Inc. (Nasdaq : EPIX) in a Rule 144A offering of convertible notes · Represented Alteon Inc. (AMEX : ALT) in various PIPE offerings · Represented Arbios Systems, Inc. (ABOS.OB) in various PIPE offerings · Represented Predix Pharmaceuticals, Inc. in its initial public offering Venture Capital Financings · Represented Anchor Therapeutics, Inc. in various Preferred Stock financings · Represented BG Medicine, Inc. in various Preferred Stock and bridge financings · Represented Aureon Laboratories, Inc. in various Preferred Stock and bridge financings · Represented Pulmatrix Inc. in its Series A financing · Represented Luminus Devices, Inc. in its Series C financing · Represented ZymeQuest, Inc. in its Series G financing Bill has lectured at various Massachusetts Continuing Legal Education seminars on topics relating to corporate organization and mergers and acquisitions. He has served as a member of the MIT Innovations Committee, which organizes presentations of the MIT Enterprise Forum. Bill is admitted to practice in Massachusetts and is a member of the American, Massachusetts and Boston Bar Associations. He is a graduate of Middlebury College and Boston University School of Law, where he served as Editor-in-Chief of the Boston University Law Review. Bill is a former law clerk to the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit. Industries Life Sciences Venture Capital and Emerging Companies Energy & Clean Technology |